Literature DB >> 11986444

Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization.

Gregory L Armstrong1, Beth P Bell.   

Abstract

OBJECTIVE: The high prevalence of antibody to hepatitis A virus (HAV) in the US population suggests that the incidence of infection is much higher than reported, but the infection rate is difficult to measure directly because of anicteric infection and underreporting. We present a model that reconciles the reported incidence of hepatitis A with the observed prevalence of antibody to HAV and provides an estimate of the true incidence of HAV infection.
METHODS: In the model, reported incidence of hepatitis A in the United States was adjusted to account first for anicteric infection and then for underreporting and declining incidence over time such that the prevalence predicted by the model approximated that observed in 2 nationwide surveys.
RESULTS: The model showed incidence in the susceptible population declining by 4.5% per year. As incidence declined early in the 1900s, the average age at infection increased, leading to a paradoxical increase in the incidence of icteric infection followed by a slow decline. The model estimated approximately 270 000 (range: 190 000-360 000) infections annually from 1980 to 1999, 10.4 times the number of hepatitis A cases actually reported during this period. More than half of these infections occurred in children who were younger than 10 years, most of which would have been clinically unrecognizable as hepatitis.
CONCLUSIONS: These results suggest a large reservoir of infection in children and that interruption of transmission in children may substantially reduce incidence of hepatitis A overall.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986444     DOI: 10.1542/peds.109.5.839

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  42 in total

1.  Hepatitis a epidemiology goes global.

Authors:  Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

2.  Immunization needs of chronic liver disease patients seen in primary care versus specialist settings.

Authors:  R Jake Jacobs; Allen S Meyerhoff; Sammy Saab
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 3.  Should all children be immunised against hepatitis A?

Authors:  Jonathan L Temte
Journal:  BMJ       Date:  2006-03-25

Review 4.  Diagnosis of hepatitis a virus infection: a molecular approach.

Authors:  Omana V Nainan; Guoliang Xia; Gilberto Vaughan; Harold S Margolis
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

5.  Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study.

Authors:  Filippo Ansaldi; Bianca Bruzzone; Maria Cristina Rota; Antonino Bella; Marta Ciofi degli Atti; Paolo Durando; Roberto Gasparini; Giancarlo Icardi
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

6.  Prevention of Viral Hepatitis.

Authors:  Raymond S. Koff
Journal:  Curr Treat Options Gastroenterol       Date:  2002-12

Review 7.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

8.  Distribution of hepatitis A antibodies in US blood donors.

Authors:  Alexandra Tejada-Strop; Mohammad Zafrullah; Saleem Kamili; Susan L Stramer; Michael A Purdy
Journal:  Transfusion       Date:  2018-10-04       Impact factor: 3.157

9.  Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement.

Authors:  R Jake Jacobs; Ronald J Moleski; Allen S Meyerhoff
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

10.  Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States.

Authors:  Peng-Jun Lu; Kathy K Byrd; Trudy V Murphy
Journal:  Vaccine       Date:  2013-03-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.